REVEAL Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 9: | Line 9: | ||
The study will evaluate the therapeutic effect of anacetrapib 100 mg on lipid profile alteration and role in reduction of cardiovascular morbidity and mortality in patients with baseline circulatory problems. | The study will evaluate the therapeutic effect of anacetrapib 100 mg on lipid profile alteration and role in reduction of cardiovascular morbidity and mortality in patients with baseline circulatory problems. | ||
==References== | ==References== | ||
Revision as of 03:39, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
REVEAL Trial On the Web |
|
American Roentgen Ray Society Images of REVEAL Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) is prospective, randomized, multicenter, placebo-controlled, double-blind clinical trial that will enroll 30,000 patients with high low density lipoprotein (LDL) receiving HMG-CoA reductase inhibitor (statin) therapy.
The study will evaluate the therapeutic effect of anacetrapib 100 mg on lipid profile alteration and role in reduction of cardiovascular morbidity and mortality in patients with baseline circulatory problems.